Fig. 7: Ahr promotes the transcription of Ikzf3 epigenetically.
From: Tissue signals imprint Aiolos expression in ILC2s to modulate type 2 immunity
a mRNA expression of Ikzf3 in IL-33-treated ILC2s for 7 days was analyzed by real-time RT-PCR. b Genome browser tracks of tissue ILC2 ATAC-seq peaks with published ATAC-seq peaks and ChIP-seq peaks at the Ikzf3 locus. From top to bottom: ATAC-seq data on tissue ILC2s; published ATAC-seq data performed using Ahr-deficient and control ILC2s of Rag1–/– mouse; published ChIP-seq data on small intestinal ILC2s; published ATAC-seq data on small intestinal ILC2s, ILC1s and ILC3s. Boxes highlight OCRs. Red boxes highlight Ahr-dependent OCRs. c Mixed bone marrow cells at 1:1 ratio from CD45.2-Ahr-deficient and CD45.1-wild-type mice were transferred to half-lethally irradiated Rag2–/–Il2rg–/– mice. Six weeks later, expression of Aiolos was analyzed by flow cytometry. Percentages of Aiolos+ cells gated on Lin–non-ILC2s (CD45+Lin–GATA3low and negative) ILC2s from indicated origins are shown. d–g ChIP Q-PCR was performed on Ahr-deficient or wild-type (WT) ILC2s using IgG control, or α-Ahr, or α-H3K27ac antibodies. Relative enrichment of Ahr (d and e) or H3K27ac (f and g) at indicated locus marked in (b) normalized to IgG control group of WT-ILC2s is shown.
